Navigation Links
French Ship docks in Alang, Gujarat

The Blue Lady, known as a jewel in the French shipping industry has anchored in the Western Indian port of Alang, the world’s biggest breaking yard, in the Gujarat State//. Asbestos –lined former ocean liner, this ship has come to India to be scrapped.

Environmentalists are up in arms against this move, due to the fear of toxic waste that will pollute the environment during the scrapping exercise. The ship contains 1,200 tonnes of cancer-causing toxic waste which the workers at Alang cannot handle effectively. Greenpeace and other groups have pointed a finger at the pressure tactics which the courts have succumbed to, making the consent for such a scrapping exercise in India possible.

It was only in February that the French government after much deliberation had recalled the decommissioned aircraft carrier Clemenceau which was on its way to Alang, after an exhaustive drive launched by Greenpeace and other environmental groups.


'"/>




Page: 1

Related medicine news :

1. French Fries In Cancer Controversy In China
2. French and wine: inseparable and just perfect?
3. French Doctors Successfully Separate Twins Joined At Spine
4. McDonalds: French Fries, Transparent to more Trans -Fats
5. Chikungunya Epidemic On French Island Claims 52 lives
6. French fries by McDonalds fries in another controversy
7. French Minister To Visit La Reunion Island To Monitor Chikungunya Epidemic
8. Chikungunya Fever: French Government struggling to Tackle the Mosquito Menace
9. New Breast Cancer Dictionary To Be Brought Out By French League Against Cancer
10. French Face Transplant Patient Reports Feeling of Sensation in New Face
11. French Surgeons Take Off for First Gravity-free Surgery

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: French Ship docks Alang Gujarat

(Date:12/2/2009)...ng medical device software engineering consulting ... certification. A relatively few medical device so...achieved ISO 13485 certification. Many medical dev... to other ISO standards as well. However, it is so...ing consulting firm to achieve the rigorous qualit...
(Date:12/2/2009)...Newswire/ -- A randomized, controlled study compar...nvasive treatment called percutaneous disc decompr...ile both treatments help patients in the short run...up to two years later. Results of the study, the f...al meeting of the Radiological Society of North Am...
(Date:12/2/2009)...asound of suspicious areas of the breast, includin...ternative to invasive biopsies for women under age...ented today at the annual meeting of the Radiologi...rming high-quality breast ultrasound, we can reduc...iagnostic procedures in young women," said senior ...
(Date:12/1/2009)...ate Christ Medical Center in Oak Lawn, Ill. has be...nter and the first for Chicago’s south and s... hospital’s plans today (December 1) by the ...rd. , Springfield, Ill. (...Lawn, Ill. has become the state’s newest kid...
(Date:12/1/2009)...c. 1 Reportlinker.com announces th...s catalogue: ,, The Future of Monoclonal Antib...hmarking, Product Pipeline and Deals Analysis ,...e-of-Monoclonal-Antibodies---Market-Forecasts-to-2...Deals-Analysis.html ,, Summary ,, The au...
Breaking Medicine News(10 mins):Health News:Medical Device Software Engineering Consulting firm Full Spectrum Software Earns ISO 13485 Certification 2Health News:Outpatient Disc Treatment Gives Long-Term Back Pain Relief 2Health News:Outpatient Disc Treatment Gives Long-Term Back Pain Relief 3Health News:Targeted breast ultrasound can reduce biopsies for women under 40 2Health News:State Approves Plans For Kidney Transplants At Advocate Christ Medical Center 2Health News:State Approves Plans For Kidney Transplants At Advocate Christ Medical Center 3Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 13
...ect of hormone replacement therapy may be inhibite...eroidal anti-inflammatory pain killer, report rese...f Pennsylvania. The researchers examined t...coronary heart disease and compared them with 7,00...
...ople another reason to quit smoking, by finding th...oping depression in comparison to those who never...kers who have quit have an elevated risk of depres... style and successful smoking cessation in long ru...
...that vegetarian diet reduces risk of colon cancer ...up as appetizer reduces food intake by about 20 pe...ife factors like choosing your diet regimen or ord...t to find out whether a vegetarian diet is associa...
...lthcare scenario has emerged a heartening developm...ated Paromomycin IM injection manufactured by the...fit drug firm, for inclusion in its Model List for...rasitic disease after malaria. It is a sy...
...ests using gene sequencing is able to help confirm...ns and patients the tools for much more accurate ...e a group of more than 40 inherited and potentiall...ucts that damage organs and tissues. The g...
...t men with chronic gum disease periodontitis, may ...ss of whether they smoke. Periodontitis is...a, though recent evidence suggests the involvement... Roswell Park Cancer Institute, Buffalo. A...
Other Medicine News:Health News:Regular Smokers are at the Risk of Developing Depression 2Health News:Vegetarian Diet Could Reduce Risk of Colon Cancer 2Health News:Vegetarian Diet Could Reduce Risk of Colon Cancer 3Health News:Vegetarian Diet Could Reduce Risk of Colon Cancer 4Health News:A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List 2Health News:A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List 3Health News:New DNA Tests Advances Treatment of Lysosomal Storage Diseases 2Health News:Men With Chronic Gum Disease at Higher Risk of Tongue Cancer 2
(Date:12/2/2009)..., EAST HANOVER, N.J., Dec. 2 Nova...te-breaking presentation on Tasigna® (nilotin...eukemia, demonstrate the strength of the company,s...ients. ,, The new data, at the 51st American S...sition, highlight the company,s current therapies ...
(Date:12/1/2009)...ULA, Calif., Dec. 1 Pati... PSTX) announced today that it has appointed Marc ...al Officer, Treasurer and Corporate Secretary, rep...2008. Prior to joining Patient Safety Technologie...f Financial Officer, Treasurer and Corporate Secre...
(Date:12/1/2009)...O BEACH, Calif., Dec. 1 Reproducti...ective Single Embryo Transfer (eSET) Encouragement...ents with good embryo quality and a good prognosis...ins by transferring a single embryo. ,, The big...ay is reducing the number of multiple pregnancies,...
Breaking Medicine Technology:Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Patient Safety Technologies, Inc. Appoints Marc L. Rose, CPA (PA), Chief Financial Officer 2Reproductive Partners Announces Elective Single Embryo Transfer (eSET) Encouragement Program 2Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology 12472 1Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology 12472 2Jefferson researchers identify critical marker of response to gemcitabine in pancreatic cancer 47918 1Jefferson researchers identify critical marker of response to gemcitabine in pancreatic cancer 47918 21 in 4 nursing home residents carry MRSA 47915 11 in 4 nursing home residents carry MRSA 47915 2
...ne payment to Pharmasset , , PRINCETON, N.J., Apr...e (Roche SWX: RO, ROG; Pink Sheets: RHHBY) today a...a Phase IIb study of R7128, the nucleoside polymer... treatment of chronic hepatitis C (HCV). The trial...of R7128 in combination with Roche,s PEGASYS(R) (p...
...for Blinatumomab , , NEW YORK, April 24 Micromet...any developing novel, proprietary antibodies for t...e diseases, today held an R&D Day for investor...ork City. , , The presentations highlighted sig...TE antibody platform and included updates on: , ,...
Other Medicine Technology:Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 2Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 3Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 4
PulseOx 7500 Pulse Oximeter
Merlin Patient Care System
Safire Bi-directional Ablation Catheter
VASOVIEW® HemoPro™ Endoscopic Vessel Harvesting System
Medicine Products: